# To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

> **NCT02540369** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2150 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02540369
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-14
- **Primary completion:** 2017-09-25
- **Final completion:** 2018-01-26
- **Target enrollment:** 2150 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540369, "To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02540369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*